Intellego Technologies
Courtagefri handel på Nordnet till sista juni 2027! Har du inget konto på Nordnet så är det verkligen läge att skaffa ett. Just nu får nya kunder courtagefri handel till sista juni 2027. Läs mer om erbjudandet och skapa ditt konto här Intellego’s partner HAI Solutions has received FDA approval for QIKcap
Intellego Technologies AB (publ) (“Intellego” or the “Company”) announces that the product QIKcap, owned by its partner company HAI Solutions (HAIS), has today received approval from the U.S. Food and Drug Administration (FDA). The approval means that QIKcap may now be marketed and used within the U.S. healthcare system.
QIKcap is based on HAI Solutions’ patented technology, in which Intellego’s photochromic indicator technology constitutes an integrated and essential part of the now approved product.
Intellego holds an ownership interest of approximately 10.5 percent in HAIS and, in addition, has exclusive rights to sell QIKcap in the Chinese market. Intellego is also entitled to license revenues from global sales of the product.
“The FDA approval of QIKcap is an important milestone for HAI Solutions and enables future sales opportunities for Intellego in the Chinese market, as well as potential license revenues linked to global sales of QIKcap,” says Jacob Laurin, acting CEO of Intellego Technologies.
QIKcap is a single-use cap for intravenous access points, primarily catheters. The product combines a photochromic dosimeter and an optical lens to verify UVC exposure, with the aim of reducing the risk of intravenous contamination and bloodstream infections.
Link to HAI Solutions news: News — HAI Solutions
| Datum | 2025-12-30, kl 16:19 |
| Källa | MFN |